Precipio, INC 8-K filings

Precipio, Inc. announced its second quarter 2026 financial results, highlighting record quarterly revenue of $7.0 million and a return to positive Adjusted EBITDA of $0.4 million.

Precipio, Inc. will host a Q2-2026 Shareholder Update Call on August 17th, 2026, to discuss core business progress and include a live Q&A session.

Precipio, Inc. announced the results of its Annual Meeting held on June 15, 2026, where stockholders elected new directors and ratified the appointment of its independent auditor.

Precipio, Inc. has scheduled its Q1 2026 shareholder update call for May 18, 2026, featuring a new moderated live Q&A session.

Precipio, Inc. announced preliminary unaudited financials for Q4 and fiscal year 2025, reporting significant revenue growth and a shift to positive Adjusted EBITDA and operating cash flow.

Precipio, Inc. announced executive salary and bonus increases, alongside performance-based stock options tied to a $40 per share stock price target, effective January 1, 2026.

Precipio, Inc. announced it will host a Q3-2025 Shareholder Update Call on November 17, 2025, to discuss updates on its core businesses.

Precipio, Inc. has terminated its At-The-Market sales agreement, signaling improved financial health and a commitment to responsible capital management.

Precipio, Inc. announced the posting of an updated investor presentation, showcasing its proprietary diagnostics platform and significant market expansion opportunities.

Precipio, Inc. announced it will host a Q2-2025 Shareholder Update Call on August 14, 2025, to provide updates on its core businesses.

Precipio, Inc. announced that its stockholders approved the re-election of Ilan Danieli and David S. Cohen as Class I directors and ratified the appointment of CBIZ CPAs, P.C. as its independent registered public accounting firm for 2025 at the Annual Meeting held on June 17, 2025.

Precipio reports a 43% year-over-year revenue increase in Q1 2025, driven by growth in both its Products and Pathology Services divisions, alongside significant improvements in adjusted EBITDA and cash flow.

Precipio, Inc. will host a Q1-2025 shareholder update call on May 15th, 2025, to discuss updates on its core businesses.

Precipio Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm due to its acquisition by CBIZ CPAs P.C., and the subsequent engagement of CBIZ as the new auditor.

Precipio, Inc. will host a conference call on March 31st, 2025, to provide a corporate update for Q4 and year-end 2024.

Precipio Inc. granted stock options to its officers that will vest only if the company's stock price reaches $30.30 per share.

Precipio Inc. announced that senior management stock options will only vest if the company's share price reaches a 10-day VWAP of $30.30, five times the exercise price.

Precipio, Inc., a specialty cancer diagnostics company, will host a shareholder update call on November 18th to discuss its Q3 2024 results and core business activities.

Precipio Inc. has approved a one-time stock option repricing for employees and key contributors, effective August 31, 2024, to align with the current market value of its shares.

Precipio, Inc. will host a shareholder update call on August 19th to discuss its Q2 2024 results and core business activities.

Precipio Inc. successfully held its annual meeting, electing two Class III directors, approving executive compensation, and ratifying its independent auditor.

Precipio, Inc. has entered into a loan agreement for $250,000 with an option for an additional $250,000, to address short-term cash flow issues caused by a cybersecurity attack on Change Healthcare.

Precipio Inc. has terminated its Factoring Agreement with Culain Capital Funding, effective April 30, 2024, without incurring any penalties.

Precipio, Inc. will host a year-end 2023 shareholder update call on April 1st, 2024, to discuss the company's core businesses.